A Randomized Study of Enzalutamide in Patients With Localized Prostate Cancer Undergoing Active Surveillance
Status:
Completed
Trial end date:
2020-08-28
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to compare the time to prostate cancer progression
(pathological or therapeutic progression) between patients treated with enzalutamide versus
patients undergoing active surveillance.
Phase:
Phase 2
Details
Lead Sponsor:
Astellas Pharma Global Development, Inc.
Collaborators:
Medivation LLC, a wholly owned subsidiary of Pfizer Inc. Medivation, Inc.